The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1483
Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes
The full article is available to subscribers Subscriber Login   
Revised 12/7/16: In Table 3, footnote 1 was changed to: "Approximate WAC for 30 days' treatment with 40 units/day in prefilled pens."

The FDA has approved insulin degludec (Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the FDA; insulin detemir (Levemir) and insulin glargine (Lantus, Toujeo) were approved earlier.1,2

Like other long-acting human insulin analogs, insulin degludec is synthesized using recombinant DNA technology. It forms multihexamers in subcutaneous tissue, which delays its absorption, and binds to circulating albumin, which delays its elimination and results in a prolonged duration of action (>42 hours).3

CLINICAL STUDIES — Approval of insulin degludec was based on the results of nine open-label, active-controlled trials, which are summarized in the package insert. In eight of the trials, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes
Article code: 1483a
 Electronic, downloadable article - $25